Associated Papers
Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
Hu C et al.
Cancer Research, 2023
RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles.
Longo MA et al.
Nature Communications, 2023
Functional analysis of germline RAD51C missense variants highlight the role of RAD51C in replication fork protection.
Kolinjivadi AM et al.
Human Molecular Genetics, 2023
In Silico-Based Structural Evaluation to Categorize the Pathogenicity of Mutations Identified in the RAD Class of Proteins.
Anwaar A et al.
Acs Omega, 2023
Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.
Prakash R et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Correction: Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: Implications for Fanconi anemia and breast cancer susceptibility.
Somyajit K et al.
The Journal of Biological Chemistry, 2019
Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
Gayarre J et al.
British Journal of Cancer, 2017
Genetic testing for RAD51C mutations: in the clinic and community.
Sopik V et al.
Clinical Genetics, 2015
Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
Somyajit K et al.
Carcinogenesis, 2015
Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
Park JY et al.
Oncogene, 2014
Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.
Gevensleben H et al.
Virchows Archiv : an International Journal of Pathology, 2014
PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.
Park JY et al.
Biochimica Et Biophysica Acta, 2014
RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A et al.
Breast Cancer Research and Treatment, 2014
Germline mutations in RAD51C in Jewish high cancer risk families.
Kushnir A et al.
Breast Cancer Research and Treatment, 2012
Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families.
Osorio A et al.
Human Molecular Genetics, 2012
Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility.
Somyajit K et al.
The Journal of Biological Chemistry, 2012
A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families.
Romero A et al.
Breast Cancer Research and Treatment, 2011
RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer.
Somyajit K et al.
Carcinogenesis, 2010
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
Meindl A et al.
Nature Genetics, 2010